Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vericel CorpVCEL · Entity 4481 | Chief Medical Officer | June 26, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vericel Corp
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 75,753 |
Last balance in matching sequence
After 2026-06-26 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2026-06-26 · Exercise / conversion · Acquired 5,000 · Balance 80,753 F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 2 · 2026-06-26 · Sale · Disposed 5,000 · Balance 75,753 F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 3 · 2026-06-26 · Exercise / conversion · Acquired 5,000 · Balance 80,753 F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 4 · 2026-06-26 · Sale · Disposed 5,000 · Balance 75,753 F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.82 · Expires 2033-02-17 | Direct | 25,000 |
Reported balance
After 2026-06-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-26 · Exercise / conversion · Acquired 5,000 · Balance 25,000 F3: These options, representing the right to purchase 30,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 17, 2023, which was one quarter after the date on which the option was granted. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.82 · Expires 2033-02-17 | Direct | 20,000 |
Reported balance
After 2026-06-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-26 · Exercise / conversion · Acquired 5,000 · Balance 20,000 F3: These options, representing the right to purchase 30,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 17, 2023, which was one quarter after the date on which the option was granted. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025.
F3: These options, representing the right to purchase 30,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 17, 2023, which was one quarter after the date on which the option was granted.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 30, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001140361-26-026930 · form4.xml · derivative · entry 6 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 5,000 shares Expires 2033-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 30,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 17, 2023, which was one quarter after the date on which the option was granted. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001140361-26-026930 · form4.xml · derivative · entry 5 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 5,000 shares Expires 2033-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 30,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 17, 2023, which was one quarter after the date on which the option was granted. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 5,000 | $45.00 | $225,000.00 |
DisclosureSEC source: 0001140361-26-026930 · form4.xml · nonDerivative · entry 4 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,753 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 5,000 | $29.82 | $149,100.00 |
DisclosureSEC source: 0001140361-26-026930 · form4.xml · nonDerivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 5,000 | $45.00 | $225,000.00 |
DisclosureSEC source: 0001140361-26-026930 · form4.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,753 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 5,000 | $29.82 | $149,100.00 |
DisclosureSEC source: 0001140361-26-026930 · form4.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,375 | $0.00 Strike: $16.66 | $0.00 |
DisclosureSEC source: 0001140361-26-023988 · form4.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,625 Underlying: Common Stock · 4,375 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 26,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 6, 2019, which was one quarter after the date on which the option was granted. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 4,375 | $35.00 | $153,125.00 |
DisclosureSEC source: 0001140361-26-023988 · form4.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,753 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 4,375 | $16.66 | $72,887.50 |
DisclosureSEC source: 0001140361-26-023988 · form4.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,472 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001140361-26-013334 · form4.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,132 Underlying: Common Stock · 3,472 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 3,472 | $35.00 | $121,520.00 |
DisclosureSEC source: 0001140361-26-013334 · form4.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,556 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,472 | $10.95 | $38,018.40 |
DisclosureSEC source: 0001140361-26-013334 · form4.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006973 · form4.xml · derivative · entry 10 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F11 · price: The Fair Market Value of the vested derivative securities is $38.25 per share. F7 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. F9 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006973 · form4.xml · derivative · entry 9 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 1,500 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F6 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 1,500 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F9 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 3,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006973 · form4.xml · derivative · entry 8 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 3,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F10 · price: The Fair Market Value of the vested derivative securities is $38.09 per share. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F9 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006973 · form4.xml · derivative · entry 7 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,650 Underlying: Common Stock · 350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 20, 2025, the Reporting Person deferred the receipt of 350 shares of Common Stock and instead received 350 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F2 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 20, 2025, the Reporting Person deferred the receipt of 350 shares of Common Stock and instead received 350 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F9 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 636 | $38.25 | $24,327.00 |
DisclosureSEC source: 0001140361-26-006973 · form4.xml · nonDerivative · entry 6 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,556 F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-006973 · form4.xml · nonDerivative · entry 5 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006973 · form4.xml · nonDerivative · entry 4 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. F6 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 1,500 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 1,335 | $38.09 | $50,850.15 |
DisclosureSEC source: 0001140361-26-006973 · form4.xml · nonDerivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,192 F5 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-006973 · form4.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006973 · form4.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 20, 2025, the Reporting Person deferred the receipt of 350 shares of Common Stock and instead received 350 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-006312 · form4.xml · derivative · entry 7 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires not disclosed F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F10 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 19, 2027. The remaining RSUs will vest in annual installments on February 19, 2028, February 19, 2029, and February 19, 2030, respectively. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $38.17 | $0.00 |
DisclosureSEC source: 0001140361-26-006312 · form4.xml · derivative · entry 6 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-02-19 F9 · derivative.exercise_date: These options shall begin vesting on February 19, 2026 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 2,325 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006312 · form4.xml · derivative · entry 5 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F8 · price: The Fair Market Value of the vested derivative securities is $37.41 per share. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006312 · form4.xml · derivative · entry 4 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest on February 17, 2027. Upon the vesting of RSUs granted to the Reporting Person on February 17, 2023, the Reporting Person deferred the receipt of 3,000 shares of Common Stock and instead received 3,000 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F2 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest on February 17, 2027. Upon the vesting of RSUs granted to the Reporting Person on February 17, 2023, the Reporting Person deferred the receipt of 3,000 shares of Common Stock and instead received 3,000 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 982 | $37.41 | $36,736.62 |
DisclosureSEC source: 0001140361-26-006312 · form4.xml · nonDerivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,027 F5 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 2,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-006312 · form4.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006312 · form4.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest on February 17, 2027. Upon the vesting of RSUs granted to the Reporting Person on February 17, 2023, the Reporting Person deferred the receipt of 3,000 shares of Common Stock and instead received 3,000 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 31, 2025 Filed Feb 13, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantCommon Stock | 122 | $26.27 | $3,204.94 |
DisclosureSEC source: 0001140361-26-005413 · form5.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,684 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,652 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001140361-25-044348 · form4.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,098 Underlying: Common Stock · 1,652 shares Expires 2030-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 48,750 shares, became exercisable in quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 11, 2020. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 1,652 | $39.14 | $64,659.28 |
DisclosureSEC source: 0001140361-25-044348 · form4.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,562 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,652 | $18.00 | $29,736.00 |
DisclosureSEC source: 0001140361-25-044348 · form4.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001140361-25-033807 · form4.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 10,000 shares Expires 2030-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 48,750 shares, became exercisable in quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 11, 2020. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:06 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 10,000 | $35.77 | $357,700.00 |
DisclosureSEC source: 0001140361-25-033807 · form4.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,363 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 10,000 | $18.00 | $180,000.00 |
DisclosureSEC source: 0001140361-25-033807 · form4.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001140361-25-021415 · form4.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 10,000 shares Expires 2030-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 48,750 shares, became exercisable in quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 11, 2020. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 10,000 | $40.09 | $400,900.00 |
DisclosureSEC source: 0001140361-25-021415 · form4.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,237 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 28, 2024. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 10,000 | $18.00 | $180,000.00 |
DisclosureSEC source: 0001140361-25-021415 · form4.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001140361-25-007179 · form4.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,750 Underlying: Common Stock · 10,000 shares Expires 2030-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 48,750 shares, became exercisable in quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 11, 2020. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 10,000 | $49.53 | $495,300.00 |
DisclosureSEC source: 0001140361-25-007179 · form4.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,101 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 28, 2024. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 10,000 | $18.00 | $180,000.00 |
DisclosureSEC source: 0001140361-25-007179 · form4.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-006086 · form4.xml · derivative · entry 5 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F8 · price: The Fair Market Value of the vested derivative securities is $52.33 per share. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest in annual installments on February 22, 2026, February 22, 2027, and February 22, 2028, respectively. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-006086 · form4.xml · derivative · entry 4 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest in annual installments on February 22, 2026, February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 50% of the vested 3,000 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F2 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest in annual installments on February 22, 2026, February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 50% of the vested 3,000 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 636 | $52.33 | $33,281.88 |
DisclosureSEC source: 0001140361-25-006086 · form4.xml · nonDerivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,101 F5 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-006086 · form4.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest in annual installments on February 22, 2026, February 22, 2027, and February 22, 2028, respectively. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-006086 · form4.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest in annual installments on February 22, 2026, February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 50% of the vested 3,000 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-005658 · form4.xml · derivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 20, 2026. The remaining RSUs will vest in annual installments on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $54.31 | $0.00 |
DisclosureSEC source: 0001140361-25-005658 · form4.xml · derivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-02-20 F1 · derivative.exercise_date: These options shall begin vesting on February 20, 2025 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-005256 · form4.xml · derivative · entry 8 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F10 · price: The Fair Market Value of the vested derivative securities is $57.78 per share. F6 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 19, 2021. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.